AlloCyte Pharmaceuticals AG is the privately held Swiss company translating its proprietary

next-generation small molecule integrin pharmacology into therapies of transformative

potential
for immune-mediated diseases of high medical need.


 

 

                

AlloCyte's team has established the categorical differentiation of diverse modes of integrin inhibition based
on their downstream effect profiles (Mancuso et al 2016).

 

                                                                      Disclaimer